ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Remnant Cholesterol as a Superior Marker Over LDL-C for Hyperuricemia: A Cross-Sectional Study in Northwest China.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Hyperuricemia is a precursor to gout and is linked to various metabolic disorders. This study investigated the associations of hyperuricemia with concordant/discordant lipid phenotypes based on low-density lipoprotein cholesterol (LDL-C) and remnant cholesterol (RC). Methods: We analyzed 8,971 participants from a cluster-stratified random sample across six provinces in Northwest China. They were categorized into four groups by LDL-C and RC levels: NRC+NLDL, NRC+HLDL, HRC+NLDL, and HRC+HLDL. Multivariable logistic regression was used to assess the odds of hyperuricemia across these groups. Results: Participants in Group NRC+HLDL, Group HRC+NLDL, and Group HRC+HLDL exhibited an increased risk for hyperuricemia by 37%, 96%, and 120%, respectively (OR: 1.37, 95% CI: 1.13-1.66 for NRC+HLDL; OR: 1.96, 95% CI: 1.57-2.45 for HRC+NLDL; OR: 2.20, 95% CI: 1.82-2.65 for HRC+HLDL), relative to Group NRC+NLDL. Subgroup analyses highlighted significant interaction effects based on gender and hypertriglyceridemia, with a more pronounced association observed in female participants. Sensitivity analyses revealed Group HRC+NLDL was most closely related to HUA when stricter LDL-C cut-offs were applied. Body mass index (BMI) and waist circumference (WC) mediated 20.27% and 6.67% of this association, respectively. Conclusion: RC demonstrated a stronger association with hyperuricemia than LDL-C, partially mediated by BMI and WC. Women exhibited greater susceptibility to RC-related hyperuricemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.